Known targets — ChEMBL curated mechanism
PPARDPTGS1PTGS2dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Lysine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 2/20 | 0.74 |
| ▸ | ARG2 | P78540 | 4/20 | 0.47 |
| ▸ | ARG1 | P05089 | 3/20 | 0.47 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.45 |
| ▸ | GRM8 | O00222 | 1/20 | 0.45 |
| ▸ | GRM6 | O15303 | 1/20 | 0.45 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.45 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.45 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.45 |
| ▸ | GRM5 | P41594 | 1/20 | 0.45 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.45 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.45 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.45 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.45 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.45 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.45 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.45 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.45 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aspartic Acid SCHEMBL8508699 | 0.98 | GSR (0.71) | GSRARG2ARG1RNPEPCYP1A2 | |
| Aspartic Acid SCHEMBL8508899 | 0.98 | GSR (0.71) | GSRARG2ARG1RNPEPCYP1A2 | |
| Aspartic Acid SCHEMBL8508697 | 0.98 | GSR (0.71) | GSRARG2ARG1RNPEPCYP1A2 | |
| Aspartic Acid SCHEMBL8508901 | 0.98 | GSR (0.71) | GSRARG2ARG1RNPEPCYP1A2 | |
| Lysine SCHEMBL1425215 | 0.96 | GSR (0.80) | GSRARG2ARG1RNPEPCYP1A2 | |
| Lysine SCHEMBL20952564 | 0.96 | GSR (0.80) | GSRARG2ARG1RNPEPCYP1A2 | |
| Lysine SCHEMBL2589784 | 0.96 | GSR (0.80) | GSRARG2ARG1RNPEPCYP1A2 | |
| Lysine SCHEMBL18528930 | 0.96 | GSR (0.80) | GSRARG2ARG1RNPEPCYP1A2 | |
| Lysine SCHEMBL1425217 | 0.96 | GSR (0.80) | GSRARG2ARG1RNPEPCYP1A2 | |
| Lysine SCHEMBL31679370 | 0.96 | GSR (0.80) | GSRARG2ARG1RNPEPCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024140670-A1 | CONJUGATE AND USES THEREOF | FULL-LIFE TECHNOLOGIES HK LIMITED (CN) | 2024-07-04 | — | — | WO | claimed |
| US-5118669-A | Inhibit histamine liberation and antibody production | HITACHI CHEMICAL CO., LTD. (JP) | 1992-06-02 | — | — | US | claimed |
| WO-2024140670-A1 | CONJUGATE AND USES THEREOF | FULL-LIFE TECHNOLOGIES HK LIMITED (CN) | 2024-07-04 | — | — | WO | disclosed |
| US-20220105194-A1 | CONJUGATE COMPRISING LIGAND, SPACER, PEPTIDE LINKER, AND BIOMOLECULE | ASTELLAS PHARMA INC. (JP) | 2022-04-07 | — | — | US | disclosed |
| EP-3909606-A1 | COMPLEX COMPRISING LIGAND AND CEACAM5 ANTIBODY FAB FRAGMENT | Astellas Pharma Inc. (JP) | 2021-11-17 | — | — | EP | disclosed |
| EP-3909608-A1 | COMPLEX COMPRISING LIGAND, SPACER, PEPTIDE LINKER, AND BIOMOLECULE | Astellas Pharma Inc. (JP) | 2021-11-17 | — | — | EP | disclosed |
| CN-113301920-A | Complexes comprising ligands, spacers, peptide linkers and biomolecules | 安斯泰来制药株式会社 | 2021-08-24 | — | — | CN | disclosed |
| CN-113271973-A | Complex comprising a ligand and a CEACAM5 antibody Fab fragment | 安斯泰来制药株式会社 | 2021-08-17 | — | — | CN | disclosed |
| US-20200354403-A1 | DUAL MASS SPECTOMETRY-CLEAVABLE CROSSLINKING REAGENTS FOR PROTEIN-PROTEIN INTERACTIONS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2020-11-12 | — | — | US | disclosed |
| US-10752655-B2 | Dual mass spectrometry-cleavable crosslinking reagents for protein-protein interactions | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-08-25 | — | — | US | disclosed |
| WO-2020145227-A1 | COMPLEX COMPRISING LIGAND, SPACER, PEPTIDE LINKER, AND BIOMOLECULE | アステラス製薬株式会社 | 2020-07-16 | — | — | WO | disclosed |
| US-20030186334-A1 | KTS-disintegrins | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2003-10-02 | — | — | US | disclosed |
| EP-1322322-A2 | COMPOUNDS AND METHODS FOR INHIBITING ALPHA-1 BETA-1 INTEGRINS | Temple University of the Commonwealth System of Higher Education (US) | 2003-07-02 | — | — | EP | disclosed |
| WO-2002022571-A2 | COMPOUNDS AND METHODS FOR INHIBITING ALPHA-1 BETA-1 INTEGRINS | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2002-03-21 | — | — | WO | disclosed |
| US-6022854-A | IN SITU TREATMENT OF VASCULAR INJURY, ATHEROSCLEROSIS OR THROMBOSIS BY TARGETED DELIVERY OF A DRUG. E.G. AN ANTICOAGUANT OR ANTITHROMBIN AGENTS, CONJUGATED WITH KISTRIN; WHICH BINDS TO MEGAKARYOCYTES OR PLATELETS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-02-08 | — | — | US | disclosed |
| EP-0421682-B1 | Novel peptides, intermediates therefor, process for preparing the same, and antiallergic agents, vasodilators and immunoregulators | HITACHI CHEMICAL CO LTD (JP) | 1997-03-26 | — | — | EP | disclosed |
| WO-1994015953-A9 | PLATELET-SPECIFIC THERAPEUTIC COMPOUND AND METHOD OF TREATING PLATELET-MOBILIZING DISEASES | — | 1994-09-15 | — | — | WO | disclosed |
| US-5223487-A | Tri-, tetra-, penta- and hexapeptatides of Asp, Gly, Lys, Ser, Ala and salts | HITACHI CHEMICAL CO., LTD. (JP) | 1993-06-29 | — | — | US | disclosed |
| US-5118669-A | Inhibit histamine liberation and antibody production | HITACHI CHEMICAL CO., LTD. (JP) | 1992-06-02 | — | — | US | disclosed |
| EP-0421682-A1 | Novel peptides, intermediates therefor, process for preparing the same, and antiallergic agents, vasodilators and immunoregulators | HITACHI CHEMICAL CO., LTD. (JP) | 1991-04-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220105194-A1 | CONJUGATE COMPRISING LIGAND, SPACER, PEPTIDE LINKER, AND BIOMOLECULE | MUC1, CA14, CA13 | GSR 4068/4885ARG2 2402/4885ARG1 1809/4885 |
| US-10752655-B2 | Dual mass spectrometry-cleavable crosslinking reagents for protein-protein interactions | TIMCC, DCLRE1A, MTCL3 | GSR 4137/4885ARG2 2959/4885ARG1 3029/4885 |
| US-20200354403-A1 | DUAL MASS SPECTOMETRY-CLEAVABLE CROSSLINKING REAGENTS FOR PROTEIN-PROTEIN INTERACTIONS | TIMCC, MTCL3, DCLRE1A | GSR 4001/4885ARG2 2131/4885ARG1 2279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.